UBS Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,056
| Closed | -$1.82K | – | 10394 |
|
|
2024
Q1 | $1.82K | Sell |
4,056
-61,668
| -94% | -$46.7K | ﹤0.01% | 8043 |
|
|
2023
Q4 | $48.6K | Buy |
+65,724
| New | +$47.9K | ﹤0.01% | 6546 |
|
|
2023
Q3 | – | Sell |
-68
| Closed | -$127 | – | 10163 |
|
|
2023
Q2 | $127 | Sell |
68
-118
| -63% | -$389 | ﹤0.01% | 8470 |
|
|
2023
Q1 | $689 | Buy |
+186
| New | +$859 | ﹤0.01% | 8927 |
|
|
2022
Q3 | – | Sell |
-123
| Closed | -$3K | – | 11203 |
|
|
2022
Q2 | $3K | Buy |
+123
| New | +$2.89K | ﹤0.01% | 9406 |
|
|
2022
Q1 | – | Sell |
-372
| Closed | -$21K | – | 11133 |
|
|
2021
Q4 | $21K | Buy |
372
+113
| +44% | +$7.59K | ﹤0.01% | 7804 |
|
|
2021
Q3 | $19K | Buy |
259
+253
| +4,217% | +$19.4K | ﹤0.01% | 7234 |
|
|
2021
Q2 | $1K | Sell |
6
-140
| -96% | -$15.5K | ﹤0.01% | 9219 |
|
|
2021
Q1 | $22K | Buy |
146
+5
| +4% | +$906 | ﹤0.01% | 7306 |
|
|
2020
Q4 | $19K | Buy |
141
+68
| +93% | +$11K | ﹤0.01% | 6995 |
|
|
2020
Q3 | $11K | Sell |
73
-209
| -74% | -$34.1K | ﹤0.01% | 6795 |
|
|
2020
Q2 | $49K | Buy |
282
+275
| +3,929% | +$46K | ﹤0.01% | 5879 |
|
|
2020
Q1 | $1K | Sell |
7
-10
| -59% | -$1.32K | ﹤0.01% | 7826 |
|
|
2019
Q4 | $2K | Sell |
17
-170
| -91% | -$19.9K | ﹤0.01% | 7871 |
|
|
2019
Q3 | $19K | Buy |
187
+127
| +212% | +$12.5K | ﹤0.01% | 6774 |
|
|
2019
Q2 | $4K | Buy |
60
+50
| +500% | +$2.83K | ﹤0.01% | 7471 |
|
|
2019
Q1 | $0 | Sell |
10
-218
| -96% | -$10.4K | ﹤0.01% | 8290 |
|
|
2018
Q4 | $8K | Buy |
228
+143
| +168% | +$10.4K | ﹤0.01% | 7367 |
|
|
2018
Q3 | $7K | Buy |
85
+34
| +67% | +$2.56K | ﹤0.01% | 7352 |
|
|
2018
Q2 | $4K | Sell |
51
-69
| -58% | -$6.02K | ﹤0.01% | 7577 |
|
|
2018
Q1 | $11K | Buy |
120
+110
| +1,100% | +$16.4K | ﹤0.01% | 6823 |
|
|
2017
Q4 | $7K | Sell |
10
-65
| -87% | -$25.1K | ﹤0.01% | 7252 |
|
|
2017
Q3 | $22K | Buy |
75
+65
| +650% | +$17.7K | ﹤0.01% | 6384 |
|
|
2017
Q2 | $2K | Sell |
10
-20
| -67% | -$5.37K | ﹤0.01% | 7409 |
|
|
2017
Q1 | $10K | Sell |
30
-12
| -29% | -$5.56K | ﹤0.01% | 6626 |
|
|
2016
Q4 | $25K | Hold |
42
| – | – | ﹤0.01% | 6381 |
|
|
2016
Q3 | $48K | Buy |
42
+5
| +14% | +$5.39K | ﹤0.01% | 5557 |
|
|
2016
Q2 | $40K | Sell |
37
-5
| -12% | -$6.28K | ﹤0.01% | 5691 |
|
|
2016
Q1 | $54K | Sell |
42
-25
| -37% | -$35.6K | ﹤0.01% | 5447 |
|
|
2015
Q4 | $165K | Sell |
67
-5
| -7% | -$7.67K | ﹤0.01% | 4821 |
|
|
2015
Q3 | $80K | Sell |
72
-9
| -11% | -$10.4K | ﹤0.01% | 5413 |
|
|
2015
Q2 | $82K | Sell |
81
-17
| -17% | -$18.3K | ﹤0.01% | 5576 |
|
|
2015
Q1 | $100K | Buy |
98
+11
| +13% | +$36.3K | ﹤0.01% | 5418 |
|
|
2014
Q4 | $290K | Buy |
+87
| New | +$267K | ﹤0.01% | 4684 |
|
Other funds holding NBSE
UBS Group's NBSE Position: Q2 2024 in Review
UBS Group sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 4,056 shares — an estimated $1.82K sold.
UBS Group first reported a position in NBSE in Q4 2014 and held it in 34 quarters. The position peaked at $290K in Q4 2014. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.
- UBS Group reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- UBS Group sold 4,056 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $1.82K.
- UBS Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2014 and held it in 34 quarters.
- UBS Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $290K in Q4 2014.
- 3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.
Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.